



Corporate Fact Sheet OTC: ACCP

Corporate Offices
2600 Stemmons Freeway,
Suite 176
Dallas, TX 75207-2107
Tel: (214) 905-5100
Fax: (214) 905-5101
<http://www.accesspharma.com>


Nanotechnology Meets Biotechnology

Company Overview

Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase 2 development, and five preclinical development programs. The Company's approved product is MuGard™ for the management of oral mucositis (a common and debilitating side effect of many cancer therapies) for which marketing authorization has been allowed by the FDA. Access' ProLindac™, a polymer-linked platinum cancer drug is in Phase 2 clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company's preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is potentially targeted to a number tumor types, including breast and ovarian; Prodrax, a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells; Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company's Cobalamin™ oral drug delivery technology.

- **MuGard™**

In the area of supportive care for cancer patients, Access has received marketing allowance for MuGard™ in the United States from the Food and Drug Administration. MuGard™ is indicated for the management of mucositis which is an ulceration of the oral cavity. Mucositis is a common and debilitating side effect of many cancer treatments. The addressable worldwide market for mucositis is estimated to be in excess of \$1 billion annually. MuGard™ provides a protective coating to the mucosal surfaces in the mouth. A clinical study has shown MuGard™ to be effective in lowering the incidence and severity of mucositis.



- **ProLindac™**

The company's lead drug candidate, ProLindac™, is currently in a Phase 2 trial in Europe in ovarian cancer patients. ProLindac™ applies the principles of nanoparticulate prodrugs to enhance the delivery of a platinum drug to tumors. In preclinical models ProLindac™ protects normal tissue from the cytotoxic platinum while in circulation and enhances uptake of drug to tumors, where the platinum is released by virtue of a pH-sensitive linker. Platinum-based drugs are among the largest classes of chemotherapeutic compounds. The drug used in ProLindac™ is DACH platinum, which is also the active moiety of oxaliplatin (Eloxatin; Sanofi-Aventis), a drug for cancer patients which has annual sales of \$2+ billion worldwide.

- **Cobalamin™ - Coated Nanoparticles**

The company also has Cobalamin™ technologies in early-stage development. These technologies are based upon the use of Cobalamin™-coated nanoparticles, for enhanced targeting of drugs to sites of disease (utilizing the increased demand for cobalamin that occurs at disease sites, such as cancer). The company also has extensive intellectual property surrounding the use of this technology for oral drug delivery including oral delivery of insulin. While oral delivery is by far the preferred route of administration for most drugs, this route is not available to many existing and/or promising therapeutic compounds because of their physical and chemical properties. Cobalamin™-coated nanoparticles provide an opportunity for oral delivery of such compounds by utilizing the body's natural uptake mechanisms.

Select Financial Data:

Share Price (2/1/08):	\$2.80	52-Week Price Range:	\$2.10-10.66
Shares Outstanding:	17.3 million (includes cs and ps)	Market Cap:	\$48 million


NanoPolymer Platform Technology

Access leverages its proprietary NanoPolymer technology platforms to generate NCEs (new chemical entities) with enhanced drug effectiveness while decreasing side effects. Nanoparticulate delivery systems can be used to (1) enhance drug absorption, (2) facilitate sustained targeted delivery, (3) enable oral bioavailability of previously injectable drugs, and (4) mediate side effects.

Recent Company Announcements

- Jan 29, 2008: Access Pharmaceuticals Announces \$2.7 Million New Equity
- Jan 14, 2008: Access Licenses MuGard™ to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
- Jan 07, 2008: Access Pharmaceuticals Closes Acquisition of Somanta Pharmaceuticals

Access' Product Pipeline Chart



Management Team

Jeffrey B. Davis, Chairman and Chief Executive Officer
SCO Financial Group LLC

**Esteban Cvitkovic, M.D., Vice Chairman (Europe),
Senior Director, Clinical Oncology R&D**
Founder, Cvitkovic & Associates Consultants (now owned by AAI Oncology)

David P. Nowotnik, Ph.D., Senior Vice President R&D
Sr. Dir. Prod Dev, Guilford ☒ Bristol-Myers Squibb ☒ Amersham International

Phillip Wise, V.P. Business Development & Strategy
VP, Com and Bus Dev & CFO, Enhance Pharmaceuticals ☒ Glaxo Wellcome

Stephen B. Thompson, Vice President, CFO
Controller, Robert E. Woolley Inc. ☒ OKC Limited Partnership ☒ Sante Fe



Investment Highlights

- Focus on Oncology
 - MuGard™ market allowance received for potential \$1 billion cancer supportive care market
 - ProLindac™ has a positive profile compared to oxaliplatin, a \$2+ billion product
- Experienced management team
- Product portfolio breadth
- Strong IP position
- Numerous strategies to create shareholder value
 - Multiple product opportunities
 - Broad technology base

For more information:

Investor Relations:

Donald C. Weinberger
Wolfe Axelrod Weinberger LLC
(212) 370-4500

Michael Wachs, CEOcast, Inc.
(212) 732-4300

This fact sheet includes historical information and forward-looking actions that Access anticipates, based on certain assumptions. Actual results could be different from projections, and Access assumes no obligation to update this information.

The risks associated with the Company are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and other reports filed by the Company with the Securities